Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
DPP Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
Yuichiro Tamaki, leader of the Democratic Party for the People (DPP), said on April 16 that he plans to submit an emergency policy proposal to the health minister calling for a “freeze” on off-year drug price revisions and price increases…
To read the full story
Related Article
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability
January 22, 2026
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
REGULATORY
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
- Label Revised for DMD Drug Viltepso Based on PIII Miss
August 18, 2026
- Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…